Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib +/- Savolitinib in MET+ EGFR+ NSCLC
NCT05163249Phase 2Active, not recruiting
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- May 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of savolitinib in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Started May 2022; status: active, not recruiting.
02
Drugs
savolitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05163249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05163249.